CNS PharmaceuticalsCNS PharmaceuticalsCNS Pharmaceuticals
  • Brain
    • Glioblastoma
    • Anthracyclines
    • Blood Brain Barrier
  • Technology
    • Berubicin
    • Pipeline
  • Team
    • Management
    • Board
  • About Us
  • Contact
  • Investors
  • Sign Up

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Analyst Coverage
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues

Mar 13, 2023 7:05am EDT

CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland

Mar 09, 2023 9:05am EST

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

Feb 07, 2023 8:45am EST

CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland

Jan 12, 2023 8:45am EST

CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event

Jan 05, 2023 9:05am EST

CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors

Jan 03, 2023 12:00pm EST

CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

Dec 08, 2022 9:08am EST

CNS Pharmaceuticals to Participate at the Virtual Investor "Ask the CEO" Event

Dec 05, 2022 8:05am EST

CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price

Nov 30, 2022 10:00pm EST

CNS Pharmaceuticals Announces Reverse Stock Split

Nov 28, 2022 4:53pm EST
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...12
Next
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed

© 2023 CNS Pharmaceuticals. All Rights Reserved, CNS Pharma

  • Brain
    • Glioblastoma
    • Anthracyclines
    • Blood Brain Barrier
  • Technology
    • Berubicin
    • Pipeline
  • Team
    • Management
    • Board
  • About Us
  • Contact
  • Investors
  • Sign Up